What is claimed is:

1. Use of an ophthalmic composition in the manufacture of a medicament for the treatment myopia in a patient, the ophthalmic composition comprising:

i) a muscarinic receptor antagonist; and

ii) an adenosine receptor antagonist,

wherein

the muscarinic receptor antagonist is atropine, atropine sulfate, noratropine, atropine-N-oxide, tropine, tropic acid, atropine methonitrate, diphenhydramine, dimenhydrinate, dicyclomine, flavoxate, oxybutynin, tiotropium, hyoscine, scopolomine (L-hyoscine), hydroxyzine, ipratropium, tropicamide, cyclopentolate, pirenzepine, homatropine, solifenacin, darifenacin, benzatropine, mebeverine, procyclidine, aclidinium bromide, trihexyphenidyl/benzhexol, tolterodine, or a pharmaceutically acceptable salt thereof,

the adenosine receptor antagonist is a xanthine derivative, caffeine or a pharmaceutically acceptable salt thereof, and

the muscarinic receptor antagonist is present in an amount in the range from between approximately 0.001 wt.% to less than 0.05 wt.%, relative to the ophthalmic composition,

the ophthalmic composition is to be administered to the patient.

2. The use of claim 1, wherein the muscarinic receptor antagonist is atropine, or a pharmaceutically acceptable salt thereof.

3. The use of any one of claims 1-2, wherein the adenosine receptor antagonist is present in an amount in the range of between approximately 0.1-5.0 wt.%, relative to the ophthalmic composition.

4. The use of any one of claims 1-3 wherein the muscarinic receptor antagonist is atropine and is present at a concentration in the range of approximately 0.01-0.04%, an adenosine receptor antagonist is caffeine and is present at a concentration in the range of approximately 0.5-3.0%, relative to the ophthalmic composition.

5. The use of any one of claims 1-4, wherein:

i) the ophthalmic composition does not increase the photopic pupil size of an eye beyond 2 mm; and/or

ii) the ophthalmic composition does not decrease the amplitude of accommodation of the eye beyond about 6.0D.

6. The use of any one of claims 1-5, wherein the ophthalmic composition is a topical ophthalmic composition.

7. The use of any one of claims 1-6, wherein the ophthalmic composition is contained within an ophthalmic device.

8. The use of claim 7, wherein the ophthalmic device is a contact lens, an ocular insert, a corneal onlay, a corneal inlay, a nano wafer, a liposome, a nanoparticle, a punctal plug, or a hydrogel matrix with microfluid reservoir.

9. The use of any one of claims 1-8, wherein the ophthalmic composition is to be topically administered to the eye in the form of an eye drop formulation, an ocular spray formulation, or an ocular gel formulation.

10. The use of any one of claims 1-9, wherein the treatment slows or reduces the progression of myopia in the treated patient, relative to non-treatment.

11. The use of any one of claims 1-10, wherein the treated patient suffers from less severe adverse side effects, relative to atropine monotherapy.